Primary progressive multiple sclerosis
RecruitingOrelabrutinib in Patients with Primary Progressive Multiple Sclerosis
- Disease:Primary progressive multiple sclerosis
- Substances:–
France- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Back to France16 clinical trials in Gonesse, France. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in FranceEssaisCliniques.fr(opens in a new tab)
France
France
France
France
France
France
France
France
France
France
France
FranceThe busiest research cities in the country
What the registry says about research in the country
Extensive clinical trials focusing on relapsing multiple sclerosis (RMS) and various treatment approaches. Studies evaluate new therapeutic agents including remibrutinib, ofatumumab, and tolebrutinib for disease management.
Particular emphasis on comparing treatment efficacy and exploring medication administration frequencies.
Research targeting critical care conditions, including septic shock and severe infections. Investigations focus on delirium prevention and treatment alternatives for antibiotic-resistant infections.
Studies aim to improve patient outcomes in intensive care settings through innovative therapeutic strategies.
Clinical trials examining treatments for major vascular events, including stroke and cardiac conditions. Studies evaluate long-term efficacy of medications for preventing recurrent cardiovascular events.
Focus on innovative approaches to reduce cardiovascular complications and improve patient outcomes.
Tell us about your condition – we search every trial in Europe and connect you with the right site.